[ad_1] © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the…
[ad_1] © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the…
[ad_1] Here’s a roundup of top developments in the biotech space over the last 24 hours: FDA Signs Off Marker Therapeutics Cell Therapy Study In Lymphoma Setting The FDA cleared Marker Therapeutics…
[ad_1] Here’s a roundup of top developments in the biotech space over the last 24 hours: Alnylam Reports Upbeat Data From Amyloidosis Study Alnylam Pharmaceuticals Inc’s ALNY APOLLO-B Phase 3 study of…
[ad_1] Axonics Inc AXNX reported a 50% Y/Y increase in Q2 sales to $69 million, beating the consensus of $59 million. Sacral neuromodulation (SNM) revenue was $55.8 million, and Bulkamid…